Performance Governance in Pharmaceutical Organizations: A Strategic Framework for Quality, Regulatory Compliance, and Value-Based Healthcare Delivery
Year: 2026
Type: article
Abstract: Pharmaceutical organizations operate under a multidimensional definition of performance. Financial results, operational efficiency, product quality, regulatory compliance, and healthcare value are all important, yet they are frequently managed through separate functions and performance systems. This fragmentation can obscure the relationships among commercial decisions, quality outcomes, regulatory obligations, and patient-relevant value. This article develops performance governance as an integrated management approach for aligning these dimensions within a common decision architecture. The proposed framework is organized around four interdependent pillars: Quality Integrity, Regulatory Integrity, Organizational Accountability, and Healthcare Value. Quality Integrity addresses the capacity to maintain product and process reliability throughout the pharmaceutical lifecycle. Regulatory Integrity extends formal compliance toward consistent, evidence-based and transparent organizational decision-making. Organizational Accountability establishes clear decision rights, escalation mechanisms, management oversight, and responsibility for outcomes across functional and organizational boundaries. Healthcare Value connects pharmaceutical performance with the outcomes and resources relevant to patients and healthcare systems. These dimensions are consistent with lifecycle-oriented pharmaceutical quality principles, which emphasize management responsibility, process and product monitoring, corrective and preventive action, change management, and continual improvement (International Council for Harmonisation [ICH], 2008). The framework also recognizes that healthcare performance increasingly requires attention to outcomes in relation to the resources used to achieve them (Porter, 2010). Performance governance therefore extends conventional KPI-based assessment by examining how results are produced, challenged, sustained, and translated into organizational and healthcare value. The article argues that durable pharmaceutical performance depends on the integration of quality, regulatory discipline, accountability, and healthcare value into strategic and operational decision-making.
Author: Maysa Meredova
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7235801993
